(I)mpact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey

摘要

The IDEA study showed that the type and duration of adjuvant chemotherapy might be adjusted according to the schedule of chemotherapy (5-fluorouracil, leucovorin, and oxaliplatin [FOLFOX] or capecitabine and oxaliplatin [CAPOX]) and the level of risk in stage III colon cancer. Hereby, we show that it has been mainly integrated in routine practice in France with a switch from 6 to 3 months and from the FOLFOX to the CAPOX regimen in patients with low-risk stage III colon cancer.